Kalohexis

Private

Private Northbrook, IL biotech developing melanocortin-system-targeted peptides for obesity, cachexia and related metabolic disorders. Spun out of parent in early 2026.

Company Info

Sector:Therapeutic Peptides

Headquarters:Northbrook, IL, USA

Founded:2026

Website:www.kalohexis.com/

Upcoming Milestones & Key Dates

2026-Q3

IPO

Confidential IPO filing (S-1)

2027-H1

regulatory

Expected IND filing for lead obesity program

Clinical Development Pipeline

Undisclosed

Target: Melanocortin-4 receptor

Obesity

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Undisclosed

Target: Melanocortin system

Cachexia

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Undisclosed

Target: Melanocortin system

Additional metabolic indications

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Obesity newcomer Kalohexis makes confidential IPO bid 3 months after spinoff ↗

Obesity newcomer Kalohexis makes confidential IPO bid 3 months after spinoff (reported by BioSpace)

Leadership Team

Careers & Job Openings

See all open roles

All departments

See company careers site

Apply Now →